64x | News
Featured news
6/25/2026
64x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturing
64x Bio
6/16/2025
64x Bio Lands $55 Million for Gene-Therapy Tech
The Wall Street Journal
1/19/2022
Press Releases
How CGT Leaders Are Reducing Failures, Scaling Processes, And Overcoming Regulatory Friction
Bioprocess Online
6/30/2025
Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models
Citeline
6/23/2025
At BIO, Companies Launch New Products for AAV Manufacturing, AI Drug Discovery
Genetic Engineering & Biotechnology News
6/20/2025
64x Bio Unveils AAV Apex Suite to Address Gene Therapy Manufacturing Bottlenecks
SynBioBeta
6/16/2025
How Church and Langer Make the Impossible Possible
Genetic Engineering & Biotechnology News
10/30/2023
Interactive snapshot: 30 promising biotech startups
Drug Discovery & Development
8/24/2023
30 biotech startups making waves
Drug Discovery & Development
8/24/2023
Here are the Bay Area's next generation of life science researchers
San Francisco Business Times
3/2/2023
The Neo CEO
Life Science Leader
3/1/2023
Top Life Sciences Startups to Watch in 2023
BioSpace
12/5/2022
Alexis Rovner of 64x Bio is building genome engineering technologies to help patients
Bloomberg
11/15/2022
Gene therapies must become miracles of medicine
The Economist
8/25/2022
The Bloomberg New Economy Catalyst List
Bloomberg
8/3/2022
Lex Rovner Wants to Transform AAV Manufacturing
ASGCT
6/2/2022
Gene therapy at the crossroads
Nature Biotechnology
5/9/2022
Ep. 100 - Four Disruptive Forces In Biotech
BioTech 2050 Podcast
4/27/2022
The 20(+1) under 40: Your guide to the next generation of biotech leaders
Endpoints News
4/19/2022
Chirps, chats and Clubhouses: First-time biotech founders turn to social media for advice, investors and recruitment
Endpoints News
4/4/2022
The Last Major Technical Hurdle for Personalized Medicine: Manufacturability
MedTech Intelligence
2/3/2022
64x Bio’s iterative solutions to vector manufacturing pain points
BioCentury
1/21/2022
64x Bio gains funding to advance cell line engineering platform
The Science Advisory Board
1/21/2022
64x Bio nets $55m Series A
Venture Capital Journal
1/19/2022
64x Bio Raises $55M To Advance Gene Therapy Platform
Crunchbase News
1/19/2022
Here is the 10-slide deck a new biotech company addressing a critical gene-therapy bottleneck used to raise $55 million in just a few months
Business Insider
1/19/2022
1/19/2022
A George Church spinout fighting the viral vector bottleneck in cell and gene therapy lands $55M
Endpoints News
1/19/2022
Harvard offshoot 64x Bio nets $55M in series A funding to expand cell production tech
Fierce Pharma
1/19/2022
1/19/2022
The Top 100 Yale Alumni In Technology of 2021
Key Executives
6/25/2021
Introducing the Wyss Lumineers Class of 2020
Wyss Institute
2/24/2021
International Day of Women and Girls in Science
Longevity Technology
2/11/2021
Viral vector start-up aims to tackle gene therapy Longevity bottleneck
Longevity Technology
12/3/2020
64x claims cell screening tech is breakthrough for global vector supplies
Bioprocess International
11/25/2020
George Church backs a startup solution to the massive gene therapy manufacturing bottleneck
Endpoints News
11/20/2020
64x Bio Emerges from Stealth to Drive an Evolution in Cell and Gene Therapy Manufacturing
64x Bio
11/16/2020